
Novo Nordisk and AWS push agentic AI deeper into drug discovery
Novo Nordisk is expanding AWS AI across drug discovery, adding AI agents and a London co-innovation hub. For technology leaders, the deal signals how enterprise-scale AI adoption can evolve into regulated R&D transformation, with new trade-offs in governance, cost, and vendor concentration.

Satish Kumar Mohanta
Latest editorial briefing



